Table 6.
Subsequent treatment
| TACE + lenvatinib (n = 14) |
TACE (n = 37) |
|||
|---|---|---|---|---|
| Accepted subsequent treatments | 5 | 35.7% | 23 | 62.2% |
| TACE + lenvatinib + PD-1 | 2 | 14.3% | 0 | 0.0% |
| Regorafenib + Nivolumab | 1 | 7.1% | 1 | 2.7% |
| Radiotherapy | 1 | 7.1% | 0 | 0.0% |
| TACE + PD-1 | 1 | 7.1% | 1 | 2.7% |
| TACE | 0 | 0.0% | 17 | 45.9% |
| Radiotherapy + TACE | 0 | 0.0% | 2 | 5.4% |
| Ablation + TACE | 0 | 0.0% | 1 | 2.7% |
| FOLFOX4 | 0 | 0.0% | 1 | 2.7% |
| Best Supportive Care | 9 | 64.3% | 14 | 37.8% |
Data are presented as n (%)
TACE transcatheter arterial chemoembolization, PD-1 programmed cell death-1 inhibitor